<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422277</url>
  </required_header>
  <id_info>
    <org_study_id>TZewin132015</org_study_id>
    <nct_id>NCT02422277</nct_id>
  </id_info>
  <brief_title>Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy</brief_title>
  <official_title>Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the role of extracorporeal low-intensity shock
      wave therapy in penile rehabilitation post nerve sparing radical cysto-prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients for whom nerve sparing radical cystoprostatectomy will be carrried out, penile
      rehabilitation by using low intensity extracorporeal shock wave therapy will be applied in 20
      patients, another 20 patients will receive oral phosphodiestrase type 5 inhibitorrs and 20
      patients will not receive any interventions in the control group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of sexual function by increase satisfaction and good vaginal penetration</measure>
    <time_frame>6 MOTHES</time_frame>
    <description>increase in IIEF score by 5 degrees</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>LI-ESWT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDE-5 inhibitors group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention include that patients will intke oral tablets of PDE-5 inhibitors :
- Oral intake of 50 mg once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be only followed up without any therapy for assisting erection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LI-ESWT group</intervention_name>
    <description>The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.
-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week.</description>
    <arm_group_label>LI-ESWT group</arm_group_label>
    <other_name>shock wave group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDE-5 inhibitors group</intervention_name>
    <description>The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.</description>
    <arm_group_label>PDE-5 inhibitors group</arm_group_label>
    <other_name>Sildenafil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients will be eligible if he is sexually motivated and potent men with stable
        relationship of more than 6 months duration who will undergo nerve sparing radical
        cysto-prostatectomy for organ-confined bladder cancer.

        Exclusion Criteria:

        - 1. Men with Peyronie's disease. 2. Inflammation in the shock wave area. 3. Evidence of
        disease failure after surgery. 4. Patients developing postoperative complications requiring
        hospital readmission after surgery which interferes with the process of SWL.

        5. Unstable medical or psychiatric disorder.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M. Asmy, MD</last_name>
    <role>Study Director</role>
    <affiliation>a_assmy@yahoo.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamer S. Zewin, MS</last_name>
    <phone>0402103041</phone>
    <phone_ext>01023500434</phone_ext>
    <email>ahmed.harraz@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed M. Hazrra, MD</last_name>
    <phone>0402103041</phone>
    <phone_ext>01023500434</phone_ext>
    <email>ahmed.harraz@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer E. Zewin, Fellow</last_name>
      <phone>0020502202222</phone>
      <email>zewin_tam@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed M. Harraz, MD</last_name>
      <phone>0020502202222</phone>
      <email>ahmed.harraz@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Tamer Zewin</investigator_full_name>
    <investigator_title>Clinical Fellow in Urology and Nephrology center, Faculty of Medicine, Mansoura University</investigator_title>
  </responsible_party>
  <keyword>Cystoprostatectomy</keyword>
  <keyword>Sexual function</keyword>
  <keyword>Phosphodiestrase 5 inhibitors</keyword>
  <keyword>Low intensity extracorporeal shock wave therapy</keyword>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Penile rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

